GlassScriptPhysician profile
Kimiko Moore
NPI 1750843637
$1,038.95
in general payments reported to CMS, 2019-2025
19 companies · $748 in 2025
The $748 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $291 · 2025: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,038.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $187.12 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.46 | 2025 | Jardiance |
| Sumitomo Pharma America, INC. | $103.45 | 2024-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $101.26 | 2024-2025 | Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $82.84 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $65.41 | 2024-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $44.02 | 2025 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $41.33 | 2024-2025 | |
| Exact Sciences Corporation | $40.56 | 2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $38.38 | 2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.03 | 2024-2025 | Xifaxan |
| Abbvie INC. | $34.71 | 2025 | |
| Edwards Lifesciences Corporation | $28.75 | 2025 | Sapien 3 Ultra Resilia |
| Xeris Pharmaceuticals, INC. | $24.11 | 2024 | Gvoke Hypopen |
| Globus Medical, INC. | $21.76 | 2025 | Vyrsa V1 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $21.65 | 2025 | Inspire |
| Dynavax Technologies Corporation | $20.52 | 2024 | Heplisav-B |
| Tonix Medicines, INC. | $19.00 | 2025 | Tonmya |
| Janssen Pharmaceuticals, INC | $18.59 | 2024 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimiko Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.